NEW YORK--(BUSINESS WIRE)--April 3, 2006--ImClone Systems Incorporated (NASDAQ: IMCL - News) today issued the following statement regarding the announcement that Merck KGaA, Darmstadt, Germany, has been granted marketing authorization by the European Commission to extend the use of ERBITUX® (Cetuximab), in combination with radiotherapy, to the treatment of patients with locally advanced squamous cell carcinoma of the head and neck:...
